-
公开(公告)号：US5063045A
公开(公告)日：1991-11-05
申请号：US506039
申请日：1990-04-09
申请人： Akio Namimatsu , Kouichiro Go
发明人： Akio Namimatsu , Kouichiro Go
CPC分类号： A61K49/0043 , G01N33/5088 , Y10S514/826
摘要： Antiallergic substances, are evaluated by measuring the amount of nasal secretion quantitatively using experimental animal models with nasal mucosal hypersensitivity.
摘要翻译： 通过使用具有鼻粘膜超敏反应的实验动物模型定量测量鼻分泌量来评估抗过敏物质。
-
32.发明授权Kallikrein inhibitor substance, a process for preparation and pharmaceutical compositions thereof 失效卡列瑞芬抑制剂物质，其制备方法及其药物组合物
公开(公告)号：US5057324A
公开(公告)日：1991-10-15
申请号：US221975
申请日：1988-07-20
申请人： Yoji Shibayama , Yoshio Toyomaki
发明人： Yoji Shibayama , Yoshio Toyomaki
IPC分类号： A61K35/12 , A61K38/00 , A61P25/04 , A61P29/00 , A61P37/08 , C07G99/00 , C07K1/14 , C07K14/00 , C07K14/435 , C12P1/00 , C12R1/91
CPC分类号： A61K35/36 , A61K35/76 , C12N2710/24132
摘要： A physiologically active substance is extracted from infected tissues inoculated with a poxvirus. The novel substance of the present invention has inhibitory action against the formation of kallikrein, thus is useful as drugs such as antiinflammatory, analgesic and antiallergic agents.
-
公开(公告)号：US4985354A
公开(公告)日：1991-01-15
申请号：US95821
申请日：1987-09-10
CPC分类号： C12Q1/37 , C12Q1/56 , C12Q2337/22 , G01N2333/96455 , G01N2333/96458 , G01N2400/40
摘要： A method of assaying a physiologically active substance, which comprises activating blood coagulation factor XII in plasma in the presence of said physiologically active substance being tested to convert prekallikrein in the plasma into kallikrein, and measuring the activity of kallikrein thus formed.
摘要翻译： 一种测定生理活性物质的方法，其包括在所述待测生理活性物质存在下激活血浆中的血液凝固因子XII，以将血浆中的前激肽释放酶转化成激肽释放酶，并测量由此形成的激肽释放酶的活性。
-
公开(公告)号：US4985254A
公开(公告)日：1991-01-15
申请号：US266758
申请日：1988-11-03
申请人： Jin-emon Konishi
发明人： Jin-emon Konishi
CPC分类号： A61K35/76 , A61K35/36 , C12N2710/24132
摘要： The present invention relates to physiologically active substances extracted from infected tissues inoculated with a poxvirus. The substances of the present invention have excellent actions to improve blood flow and recover functions of diseased tissues, thus are useful as drugs for various diseases caused by blood flow disorders.
-
公开(公告)号：US4708954A
公开(公告)日：1987-11-24
申请号：US826997
申请日：1986-02-07
申请人： Kazuharu Ienaga , Ko Nakamura , Akira Ishii
发明人： Kazuharu Ienaga , Ko Nakamura , Akira Ishii
IPC分类号： C07D295/20 , A61K31/445 , A61P3/08 , A61P3/10 , C07C67/00 , C07C239/00 , C07C275/50 , C07D295/10 , C07D295/215 , A61K31/535
CPC分类号： C07D295/215 , C07C275/50 , C07C2101/08 , C07C2101/14
摘要： Pharmaceutical compositions containing an oxaluric acid derivative of the formula: ##STR1## wherein each of R.sub.1 and R.sub.2, which may be the same or different, is hydrogen; an alkyl group or a cycloalkyl group; or R.sub.1 and R.sub.2 are joined to form a heterocyclic ring with the nitrogen atom to which they are both attached; and R.sub.3 is hydrogen or an alkyl group. These compounds have excellent hypoglycemic effects with low toxcicity and safety.
摘要翻译： 含有下式的草酸衍生物的药物组合物：其中R1和R2可以相同或不同，为氢; 烷基或环烷基; 或者R 1和R 2连接形成与它们相连的氮原子的杂环; 并且R 3是氢或烷基。 这些化合物具有优异的低血糖作用，具有低毒性和安全性。
-
公开(公告)号：US4647574A
公开(公告)日：1987-03-03
申请号：US709861
申请日：1985-03-08
申请人： Kazuharu Ienaga , Ko Nakamura
发明人： Kazuharu Ienaga , Ko Nakamura
IPC分类号： C07D233/66 , C07D233/72 , C07D233/74 , A61K31/415
CPC分类号： C07D233/72
摘要： The present invention relates to novel hydantoin derivatives represented by the general formula (I) and pharmaceutical compositions containing them as an active ingredient. ##STR1## In the formula (I), X is hydrogen or a group having the formula --OR.sub.4, and each of R.sub.1, R.sub.2, R.sub.3 and R.sub.4, which may be the same or different, is hydrogen, an alkyl group or a cycloalkyl group.Hydantoin derivatives and pharmaceutically acceptable salts thereof of the present invention have excellent hypoglycemic, hypolipidemic and diuretic effects, as well as low toxicity and great safety. Therefore, the compounds of the present invention are not only useful as antidiabetics but also as drugs for hyperlipidemia.
摘要翻译： 本发明涉及由通式（I）表示的新型乙内酰脲衍生物和含有它们作为有效成分的药物组合物。 （I）在式（I）中，X是氢或具有式-OR 4的基团，R 1，R 2，R 3和R 4可以相同或不同，为氢，烷基 或环烷基。 本发明的乙内酰脲衍生物及其药学上可接受的盐具有优异的降血糖，降血脂和利尿作用，并且毒性低，安全性高。 因此，本发明的化合物不仅可用作抗糖尿病药，还可用作高脂血症药物。
-
公开(公告)号：US12029751B2
公开(公告)日：2024-07-09
申请号：US18143370
申请日：2023-05-04
发明人： Hiroyuki Tanaka , Hideki Yoshikawa , Hideki Mochizuki , Tsuyoshi Murase , Tsutomu Sasaki , Kousuke Baba , Toru Iwahashi , Mitsuru Naiki
IPC分类号： A61K31/714 , A61K9/00 , A61P25/28
CPC分类号： A61K31/714 , A61K9/0019 , A61P25/28
摘要： An object is to provide a drug which is useful in treating a nervous system disease. A drug containing vitamin B12 as an active ingredient according to the present invention has an M2 macrophage/microglia induction promoting effect, an M1 macrophage/microglia induction inhibiting effect, a nerve regeneration promoting effect, and the like and is very useful as a therapeutic agent for a nervous system disease, and particularly useful as a therapeutic agent for a central nervous system disease such as cerebral infarction, dementia, or spinal cord injury.
-
公开(公告)号：US11679122B2
公开(公告)日：2023-06-20
申请号：US17748553
申请日：2022-05-19
发明人： Hiroyuki Tanaka , Hideki Yoshikawa , Hideki Mochizuki , Tsuyoshi Murase , Tsutomu Sasaki , Kousuke Baba , Toru Iwahashi , Mitsuru Naiki
IPC分类号： A61K31/714 , A61P25/28 , A61K9/00
CPC分类号： A61K31/714 , A61K9/0019 , A61P25/28
摘要： An object is to provide a drug which is useful in treating a nervous system disease. A drug containing vitamin B12 as an active ingredient according to the present invention has an M2 macrophage/microglia induction promoting effect, an M1 macrophage/microglia induction inhibiting effect, a nerve regeneration promoting effect, and the like and is very useful as a therapeutic agent for a nervous system disease, and particularly useful as a therapeutic agent for a central nervous system disease such as cerebral infarction, dementia, or spinal cord injury.
-
39.发明授权公开(公告)号：US11207354B2
公开(公告)日：2021-12-28
申请号：US16336236
申请日：2017-09-22
IPC分类号： A61K35/36 , A61P25/02 , G01N33/50 , C12N7/00 , C12Q1/6876
摘要： A Schwann cell differentiation promoting agent, a peripheral nerve regeneration promoting agent, or the like contain an extract from inflamed tissues inoculated with vaccinia virus. The extract from inflamed tissues inoculated with vaccinia virus promotes differentiation of Schwann cells and regeneration of a peripheral nerve. Therefore, a preparation containing the extract from inflamed tissues inoculated with vaccinia virus is useful as a Schwann cell differentiation promoting agent, a peripheral nerve regeneration promoting agent, or the like.
-
公开(公告)号：US20210267900A1
公开(公告)日：2021-09-02
申请号：US17255200
申请日：2019-06-25
发明人： Hiroshi SAKAMOTO , Kunio KOMAI , Kiyoshi FUKUDA , Kensuke NAMBA , Kaori SHIMOAKA
摘要： The present invention relates to a pre-processing method for the purpose of formulating a drug substance having non-uniform particle sizes by a manufacturing method having excellent manufacture performance. According to the pre-processing method of the present invention, additives including at least a dispersant are blended in a drug substance having a specific particle size distribution and then the resultant mixture is deagglomerated/sized to disperse and make adhere the additives onto the surfaces of the particles of the drug substance, thereby yielding a powder having a specified particle size distribution. In this manner, a pharmaceutical preparation can be manufactured with excellent manufacture performance, manufacture efficiency, and manufacture cost by a direct compression method, a wet continuous granulation system or the like. Therefore, the pre-processing method is very useful.
-
-
-
-
-
-
-
-
-
搜索结果
198 条记录 (耗时 0.023 秒)
